参考文献/References:
［1］ Pandey AN. Retinoblastoma: an overview［J］. Saudi J Ophthalmol, 2014, 28: 310-315.
［2］ Dimaras H, Timothy WC, Cobrinik D, et al. Retinoblastoma［J］. Int Ophthalmol, 1987, 10: 96-96.
［3］ 张 靖， 姜 华， 申 刚， 等． 经导管眼动脉灌注化疗治疗晚期视网膜母细胞瘤30例［J］． 介入放射学杂志， 2014， 23： 31-34．
［4］ 张 靖， 赵军阳， 项道满， 等． 经导管眼动脉灌注化疗治疗眼内晚期视网膜母细胞瘤化疗失败患者的价值［J］． 中华放射学杂志， 2014， 48： 577-581．
［5］ Abramson DH, Dunkel IJ, Brodie SE, et al. A phase Ⅰ/Ⅱ study of direct intraarterial（ophthalmic artery） chemotherapy with melphalan for intraocular retinoblastoma initial results［J］. Ophthalmology, 2008, 115: 1398-1404.
［6］ Eagle RC Jr. High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study［J］. Arch Pathol Lab Med, 2009, 133: 1203-1209.
［7］ Shields CL, Manjandavida FP, Lally SE, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma［J］. Ophthalmology, 2014, 121: 1453-1460.
［8］ Peterson EC, Elhammady MS, Quintero-Wolfe S, et al. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors［J］. J Neurosurg, 2011, 114: 1603-1608.
［9］ Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada［J］. J Natl Cancer Inst, 2000, 92: 205-216.
［10］ Shields CL, Shields JA, Baez K, et al. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors［J］. Cancer, 1994, 73: 692-698.
［11］ Masera G. The incidence of childhood cancer is growing. What shall we do?［J］. Epidemiol Prev, 2009, 33: 132.
［12］ Brichard B, De Bruycker JJ, De Potter P, et al. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma［J］. Med Pediatr Oncol, 2002, 38: 411-415.
［13］ 刘秋玲， 王亚峰， 毛更生， 等． 眼动脉介入化疗治疗眼内期视网膜母细胞瘤 42 例临床安全性分析［J］． 中华儿科杂志， 2012， 50： 793-797．
［14］ Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience［J］. Arch Ophthalmol, 2011, 129: 732-737.
［15］ Shields CL, Kaliki S, Shah SU, et al. Minimal exposure（one or two cycles） of intra-arterial chemotherapy in the management of retinoblastoma［J］. Ophthalmology, 2012, 119: 188-192.
［16］ Suzuki S, Yamane T, Mohri M, et al. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis［J］. Ophthalmology, 2011, 118: 2081-2087.
［17］ Marees T, Van Leeuwen FE, De Boer MR, et al. Cancer mortality in long-term survivors of retinoblastoma［J］. Eur J Cancer, 2009, 45: 3245-3253.
［18］ Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma［J］. J Clin Oncol, 2000, 18: 12-17.
［19］ Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death［J］. Br J Ophthalmol, 2009, 93: 1129-1131.
［20］ Hayreh SS. Orbital vascular anatomy［J］. Eye （Lond）, 2006, 20: 1130-1144.
［21］ Hayreh SS, Dass R. The ophthalmic artery: I.origin and intra-cranial and intracanalicular course［J］. Br J Ophthalmol, 1962, 46: 65-98.
［22］ Marr BP, Hung C, Gobin YP, et al. Success of intra-arterial chemotherapy （chemosurgery） for retinoblastoma: effect of orbito-vascular anatomy［J］. Arch Ophthalmol, 2012, 130: 180-185.